VENLO, Netherlands, June 3, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, June 10, 2009. The conference is being held at Grand Hyatt Hotel in New York, NY.
Peer M. Schatz, QIAGEN's Chief Executive Officer, will provide an overview of the company, discuss QIAGEN's business as well as recent developments and outline future opportunities. QIAGEN's presentation will be audio webcasted live for investors and available for replay for a period of 90 days following the conference. The presentation can be accessed in the Investor Relations section at http://www.qiagen.com.
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.
The QIAGEN N.V. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3692